1,415 followers
@dougbeall So we have trials that are either equivocal, or too flawed methodologically to conclude much of anything. Meanwhile very real potential for harm and unclear benefit https://t.co/21s2TxcpKs
@dougbeall So we have trials that are either equivocal, or too flawed methodologically to conclude much of anything. Meanwhile very real potential for harm and unclear benefit https://t.co/21s2TxcpKs
@AlmquistNicki Where is the [only worthwhile] between-group comparison? Not in the abstract... E.g. https://t.co/K98wXFuqkb
RT @5_utr: 🛑 looking at change scores / change from baseline as an endpoint❗️ https://t.co/G7UOz5IjKU
🛑 looking at change scores / change from baseline as an endpoint❗️ https://t.co/G7UOz5IjKU